Abstract
Light chain multiple myeloma (LCMM) initiates approximately 15 percentage of patients with multiple myeloma (MM). It has a lower prognosis when compared with the variant immunoglobulin (Ig) G or IgA. We report a rare case on Light chain multiple myeloma in 49-year-old male patient who presented with acute kidney injury, hypercalcemia. histopathology examination was found to be plasmacytoma, kappa restricted; and free kappa lamda chain in urine and serum was found to be greater. Bone pain and renal dysfunction were the most common prevalent initial signs and symptoms while extramedullary disease (EMD) was later acquired during disease. Bortezomib demonstrated superior efficacy over nonbortezomib in LCMM patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
